TY  - GEN
AU  - Dy,Grace K
AU  - Nesline,Mary K
AU  - Papanicolau-Sengos,Antonios
AU  - DePietro,Paul
AU  - LeVea,Charles M
AU  - Early,Amy
AU  - Chen,Hongbin
AU  - Grand'Maison,Anne
AU  - Boland,Patrick
AU  - Ernstoff,Marc S
AU  - Edge,Stephen
AU  - Akers,Stacey
AU  - Opyrchal,Mateusz
AU  - Chatta,Gurkamal
AU  - Odunsi,Kunle
AU  - Pabla,Sarabjot
AU  - Conroy,Jeffrey M
AU  - Glenn,Sean T
AU  - DeFedericis,Hanchun T
AU  - Burgher,Blake
AU  - Andreas,Jonathan
AU  - Giamo,Vincent
AU  - Qin,Maochun
AU  - Wang,Yirong
AU  - Kanehira,Kazunori
AU  - Lenzo,Felicia L
AU  - Frederick,Peter
AU  - Lele,Shashikant
AU  - Galluzzi,Lorenzo
AU  - Kuvshinoff,Boris
AU  - Morrison,Carl
TI  - Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
SN  - 1472-6947
PY  - 2019///0715
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Genetic Profile
KW  - High-Throughput Nucleotide Sequencing
KW  - standards
KW  - Humans
KW  - Neoplasms
KW  - drug therapy
KW  - Pharmacogenomic Testing
KW  - Precision Medicine
KW  - Retrospective Studies
KW  - United States
KW  - United States Food and Drug Administration
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1186/s12911-019-0743-x
ER  -